reports
Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neo...
Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at , or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help ...
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeuti...
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at , or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders...
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Sto...
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 – Record date for each Special Meeting of Stockholders is February 5, 2021 – – Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. – ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage ph...
Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Con...
Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a pre-recorded presentation as part of the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available for on-demand viewing on the Investor Relations page of the company’s website...
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agree...
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class prescription therapeutic...
Neos Therapeutics Reports Third Quarter 2020 Financial Results
Neos Therapeutics Reports Third Quarter 2020 Financial Results – Company to host conference call today at 8:30 a.m. EDT – DALLAS and FORT WORTH, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the third quarter ended September 30, 2020 and provided a business update. “During the third quarter, we saw Neos ADHD prescription volumes and the overall ADHD market begin to rebound from the profound impact of the ...
Neos Therapeutics to Host Third Quarter 2020 Financial and Operating R...
Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020 DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its third quarter 2020 financial results at the opening of U.S. financial markets on Monday, November 9, 2020. Neos management will host a conference call and live audio webcast to discuss these results and provide a company upd...
Neos Therapeutics to Present at Cantor Virtual Global Healthcare Confe...
Neos Therapeutics to Present at Cantor Virtual Global Healthcare Conference DALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020, at 3:40 p.m. ET. A live webcast of the fireside chat will be available on the Investor Relations page ...
Neos Therapeutics Reports Second Quarter 2020 Financial Results
Neos Therapeutics Reports Second Quarter 2020 Financial Results – Company to host conference call today at 8:30 a.m. EDT – DALLAS and FORT WORTH, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the second quarter ended June 30, 2020 and provided a business update. “We believe the future potential of our ADHD portfolio is strong following our recent sales force re-alignment and the continued growth o...
Neos Therapeutics to Host Second Quarter 2020 Financial and Operating ...
Neos Therapeutics to Host Second Quarter 2020 Financial and Operating Results Conference Call on August 10th, 2020 DALLAS and FORT WORTH, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its second quarter 2020 financial results at the opening of U.S. financial markets on Monday, August 10, 2020. Neos management will host a conference call and live audio webcast to discuss these results and provide a company upd...
Neos Therapeutics to Present at BMO 2020 Prescriptions for Success Hea...
Neos Therapeutics to Present at BMO 2020 Prescriptions for Success Healthcare Conference DALLAS and FORT WORTH, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will present a company overview at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020, at 4:30 p.m. ET. A live webcast of the presentation will be available on the Investor ...
Neos Therapeutics to Present at the Jefferies Virtual Global Healthcar...
Neos Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference DALLAS and FORT WORTH, Texas, May 26, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will present a company overview at the upcoming Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020, at 9:00 a.m. ET. A live webcast of the presentation will be available on the Investor Relations p...
Neos Therapeutics Reports First Quarter 2020 Financial Results
Neos Therapeutics Reports First Quarter 2020 Financial Results – Company announces reduction in force to streamline costs and accelerate the path to profitability, particularly in light of the business impact from the COVID-19 pandemic – – Company to host conference call today at 5:00 p.m. EDT – DALLAS and FORT WORTH, Texas, May 11, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the first quarter ended March 31, 2020 and a...
Neos Therapeutics to Host First Quarter 2020 Financial and Operating R...
Neos Therapeutics to Host First Quarter 2020 Financial and Operating Results Conference Call on May 11th, 2020 DALLAS and FORT WORTH, Texas, May 04, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its first quarter 2020 financial results at the closing of U.S. financial markets on Monday, May 11, 2020. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 5:...
Neos Therapeutics Announces Issuance of New U.S. Methods of Use Patent...
Neos Therapeutics Announces Issuance of New U.S. Methods of Use Patent for N-desethyloxybutynin -- N-desethyloxybutynin is the active ingredient in NT0502, the company’s development candidate for the treatment of sialorrhea -- DALLAS and FORT WORTH, Texas, April 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,610,507, which is directed to methods of tre...
Neos Therapeutics Statement: COVID-19 Update
Neos Therapeutics Statement: COVID-19 Update DALLAS and FORT WORTH, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Jerry McLaughlin, President and CEO, made the following statement: We want to share the steps we are taking to ensure healthcare providers and patients continue to receive support from Neos Therapeutics and that we are doing our part to ensure our whole team, and the patients we serve, are safe during the COVID-19 global pandemic. To help slow the spread of COVID-19, most of our employees have been operating under a work from home policy in accordance with guidance issued by the...
Neos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial R...
Neos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results – Full year 2019 net revenues increased by 29% and operating loss decreased by $33M – – Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end – – NT0502 Phase 1 ascending dose trial initiation planned in 2H20 following top-line PK data – – Company to host conference call today at 8:30am ET – DALLAS and FORT WORTH, Texas, March 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing...
Neos Therapeutics to Host Fourth Quarter and Year-End 2019 Financial a...
Neos Therapeutics to Host Fourth Quarter and Year-End 2019 Financial and Operating Results Conference Call on March 13th, 2020 DALLAS and FORT WORTH, Texas, March 06, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its fourth quarter and year-end 2019 financial results prior to the opening of U.S. financial markets on Friday, March 13, 2020. Neos management will host a conference call and live audio webcast to discuss these re...
Neos Therapeutics to Present at the Cowen & Co. 40th Annual Health Car...
Neos Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference DALLAS and FORT WORTH, Texas, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that Jerry McLaughlin, President and Chief Executive Officer, will present a company overview at the upcoming Cowen & Co. 40th Annual Health Care Conference on Wednesday, March 4, 2020, at 11:20 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the...
Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of...
Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea New chemical entity and selective muscarinic receptor antagonist targeting large unmet need for a new treatment that can meaningfully improve the lives of patients with neurological conditions DALLAS and FORT WORTH, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it has initiated and completed dosing in a Ph...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.